BRAF V600 Mutation

Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer

A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)

A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation

To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations